Scarica l'app Stockscreener
3.00
6.01%
0.17
Precedente Chiudi:
$2.83
Aprire:
$2.886
Volume 24 ore:
160.03K
Relative Volume:
0.61
Capitalizzazione di mercato:
$98.17M
Reddito:
$1.95M
Utile/perdita netta:
$-47.84M
Rapporto P/E:
-2.0227
EPS:
-1.4832
Flusso di cassa netto:
$-27.46M
1 W Prestazione:
-0.99%
1M Prestazione:
-23.47%
6M Prestazione:
-21.88%
1 anno Prestazione:
-53.85%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$2.75
$3.10
Portata 52W:
$2.42
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.00 | 98.17M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
US Stocks Starting with I: Complete List - INDmoney
Insight Molecular Diagnostics Inc. Announces Appointment of Donnie Purto as Senior Vice President of Sales - marketscreener.com
Insight Molecular Diagnostics (NasdaqCM:IMDX) Stock Forecast & Analyst Predictions - Simply Wall Street
iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - The Manila Times
IMDX : Insight Molecular Diagnostics Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Retractable Technologies, Inc. (RVP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insight Molecular (IMDX) shifts Chronix earnout to CNI Monitor test - Stock Titan
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx executives are set to meet investors in New York - Stock Titan
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire
Here's Why We're A Bit Worried About Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Situation - Simply Wall Street
IMDX Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.73%Net Profit Margin - dars.gov.et
IMDX Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.73%EPS Growth Rate - https://www.dars.gov.et/
Guardant Health Inc (NASDAQ: GH) Share Price, GH Stock News, GH Share Price & Updates - kalkine.ca
Insight (IMDX) Earnings Report: Profit Per Share Surpasses Its Benchmark at the Close; Trading Response - careplusvn.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT) - The Globe and Mail
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com UK
Insight Molecular Q2FY26 Results: Cash burn rises to $10 million - scanx.trade
Lucid Capital Markets initiates Insight Molecular stock with buy rating - Investing.com
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateHigh Low Breadth - siam.in
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Veterinary Diagnostics Market Share | Industry Report [2034] - Fortune Business Insights
MDxHealth (MDXH) Surges 74.89% to $0.81 as Momentum Builds in Diagnostic OncologySynthetic Short - careplusvn.com
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Cardio Diagnostics Holdings Warrant (CDIOW) Holds at $0.01 as Trading Remains Highly SpeculativeMAMA Signal - careplusvn.com
Cardio Diagnostics Holdings Warrant (CDIOW) Holds at $0.01 as Trading Remains Highly SpeculativeFundamentals - dars.gov.et
Cardio Diagnostics Holdings Warrant (CDIOW) Holds at $0.01 as Trading Remains Highly SpeculativeReversal Setup Alerts - dars.gov.et
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportMomentum Stock Picks - vinanet.vn
Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - marketsandmarkets.com
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportEarnings Miss Risk - dars.gov.et
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insight Molecular Diagnostics Inc Azioni (IMDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 27 '26 |
Buy |
3.64 |
250,923 |
913,134 |
12,684,884 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 24 '26 |
Buy |
3.53 |
38,880 |
137,083 |
12,433,961 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 20 '26 |
Buy |
3.88 |
40,690 |
157,967 |
12,114,700 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 17 '26 |
Buy |
3.57 |
40,114 |
143,251 |
12,074,010 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 16 '26 |
Buy |
3.45 |
102,057 |
351,658 |
12,033,896 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 10 '26 |
Buy |
5.75 |
521,739 |
2,999,999 |
11,931,839 |
| James Andrea S. | Chief Financial Officer |
Oct 31 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
201,231 |
5.67%
6.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):